DMOAD

(redirected from Disease-Modifying Osteoarthritis Drug)
AcronymDefinition
DMOADDisease-Modifying Osteoarthritis Drug(s)
References in periodicals archive ?
The funds will be used to advance Symic Bio's disease-modifying osteoarthritis drug, SB-061, into a global Phase 2b trial to be started in the latter half of 2019 as well a global Phase 3 trial evaluating the potential for SB-030 to prevent vein graft failure in peripheral artery disease in 2020.
Galapagos is developing investigational molecule GLPG1972/S201086 with the potential to become a first-in-class disease-modifying osteoarthritis drug as part of a collaboration with Servier signed in 2010.
Even though there is still no disease-modifying osteoarthritis drug currently licensed for use, "I'm really positive about all of what we've learned, particularly with the application to future trials and ongoing trials in this space," Dr.
Is knee radiography useful for studying the efficacy of a disease-modifying osteoarthritis drug in humans?
According to the company, previous results from a phase IIa study showed that MIV-711 demonstrated benefit on joint structure and thereby has the potential to act as a disease-modifying osteoarthritis drug (DMOAD).
These drugs, known as disease-modifying osteoarthritis drugs (DMOADs), present the properties of reversing, stabilizing, or at least delaying the course of OA.
-- The Food and Drug Administration appears to be poised to redefine osteoarthritis progression as its required pivotal outcome measure in clinical trials aimed at earning approval for disease-modifying osteoarthritis drugs.
Efforts to identify disease-modifying osteoarthritis drugs (DMOADs) have been hampered by several factors, but the focus has now shifted toward the validation of chemical and imaging biomarkers that should aid in DMOAD development.
Progress in understanding its pathophysiological processes has led to the identification of promising therapeutic targets, with disease-modifying osteoarthritis drugs (DMOADs) having the most potential.
Although the development of disease-modifying osteoarthritis drugs (DMOADs) is a rather complex process, the large body of new information generated by research provides guidance in the development of new and novel therapeutic strategies to delay the progression of structural changes in OA.
The search for disease-modifying osteoarthritis drugs, DMOADs, has been hampered by several factors, including the variable progression of disease, the lack of specificity and sensitivity of standard radiography, and the fact that the slowing of radiographic progression may not result in corresponding improvement in pain and function.